About RECBIO-B Company

Jiangsu Ruike Biotechnology Co., Ltd. (“Ricoh Biotech” or the “Company”) is an innovative vaccine company committed to developing and commercializing safer and more effective innovative vaccines to address public health needs that are far from being met. Ricoh Biotech has high-value vaccine packages and is driven by self-developed novel adjuvant technology and protein engineering technology. Through the company's strong R&D capabilities, a powerful innovative vaccine portfolio composed of 11 vaccine candidates has been established, and coverage has been strategically expanded to include 5 of the 10 most burdensome diseases in the “Global Burden of Disease” assessed by DALYs published by the World Health Organization in 2019, and the disease fields covered by 3 of the 5 best-selling vaccine products in the world in 2020. Currently, the company's core product, REC603, a recombinant HPV nine-valent vaccine, is in phase III clinical trials. The company has formulated a clear commercialization strategy in China and overseas with the aim of further penetrating diversified markets around the world. At the same time, the company has developed three advanced technology platforms for novel adjuvant development, protein engineering, and immune evaluation. These platforms enable companies to continuously discover and develop innovative vaccines and apply advanced technology to vaccine candidates. The company completed Series A financing in 2019, Series B financing in 2020, and completed Series B+ financing and Series C financing in 2021, respectively.